Search results for "investments"
Article
CDMOs Driving Emerging Bio/Pharma Success
CDMOs Driving Emerging Bio/Pharma Success
CDMOs can claim credit for the robust growth of emerging bio/pharma financings.
By Jim Miller
Emerging bio/pharmaceutical companie…
Article
From Darwin to Recombinant Fc Multimers
…patient safety vigilance, clarity on reimbursement and other policies, and continued innovation and investments.
Of special interest to the audience was how the acquisition of BPL last year by th…
Article
The Tide Stays High
Funding and investments
One positive indicator for CDMOs and CROs is the robustness of venture capital investment. Venture capital money has always been more dependable than public equity, even du…
Article
Modern Manufacturing Systems Key to FDA Quality Initiative
Apr 02, 2015
By Jill Wechsler
Pharmaceutical Technology
Volume 39, Issue 4
To ensure patient access to high quality, safe, and effective medicines, FDA spends considerable time and resou…
Article
Science Focus Fuels Successful Process Development for Startups
Getting the science right helps biopharma startups overcome development and commercialization challenges.
By Cynthia A. Challener
sdecoret/Stock.Adobe.com
Pr…
Article
A Plastic Pipeline for Commercial Bioprocessing?
A Plastic Pipeline for Commercial Bioprocessing?
The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.
By Rita C. Peters
…
Article
Patenting Prospects for Cell-Based Therapies
Nevertheless, if these investments are to be made, exclusivity—particularly patent exclusivity—will be crucial. The present patent landscape in the United States provides little comfort that these exc…
Article
Contract Manufacturing Through the Years
Contract Manufacturing Through the YearsHow has the bio/pharmaceutical contract manufacturing industry evolved over the years and what does the future hoHow has the bio/pharmaceutical contract ma…
Article
Biopharma Advances Demand Specialized Expertise
…hnologies?
Patel (Catalent Pharma Solutions): Catalent Pharma Solutions has significant ongoing investments in enhancing our large-molecule analytical capabilities and productivity to meet and ad…
Article
Monoclonal Antibodies Key to Unlocking the Biosimilars Market
“Since 2002, we have made significant investments in facilities, human resources, and technology to become a global and innovative biopharmaceutical company,” he says.
Need for clear regulatory pa…